0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Metachromatic Leukodystrophy Treatment Market Research Report 2022
Published Date: August 2022
|
Report Code: QYRE-Auto-19C11546
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Metachromatic Leukodystrophy Treatment Market Research Report 2022

Global Metachromatic Leukodystrophy Treatment Market Research Report 2022

Code: QYRE-Auto-19C11546
Report
August 2022
102 Pages
QYResearch
Region: Global
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
Metachromatic leukodystrophy disease (MLD) is a deadly genetic condition caused by mutations in the ARSA gene that results in brain impairment and developmental retardation. In its most severe and prevalent forms, young children rapidly lose their capacity to walk, communicate, and interact with their surroundings, and the majority die before reaching puberty.Metachromatic leukodystrophy is characterized by sulfatide deposition in cells. This accumulating has a particular impact on nervous system cells that create myelin, a material that insulates and protects neurons. White matter is a tissue made composed of nerve cells coated with myelin. This damages the protective myelin sheathing the neurons, leading to gradual deterioration of the brain and nervous system functioning.This disease has three forms that are Late Infantile Form, Juvenile Form, and Adult Form. Pipeline products, which can only treat symptoms of the disease, are among the medical treatment. These products have the potential to prevent nerve damage, reduce the development of the illness, avoid complications, and provide pain relief.
Highlights

The global Metachromatic Leukodystrophy Treatment market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.

North American market for Metachromatic Leukodystrophy Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

Asia-Pacific market for Metachromatic Leukodystrophy Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The global market for Metachromatic Leukodystrophy Treatment in Hospital is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The major global companies of Metachromatic Leukodystrophy Treatment include ArmaGen, Inc., GlaxoSmithKline Plc, Recursion Pharmaceuticals, Inc., RegenxBio, Inc., Takeda Pharmaceutical Company Limited, Orchard Therapeutics Plc, Magenta Therapeutics, Shire Plc and Oxyrane, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.

Considering the economic change due to COVID-19, Tablet, which accounted for % of the global market of Metachromatic Leukodystrophy Treatment in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Metachromatic Leukodystrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metachromatic Leukodystrophy Treatment.
The Metachromatic Leukodystrophy Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Metachromatic Leukodystrophy Treatment market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metachromatic Leukodystrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
ArmaGen, Inc.
GlaxoSmithKline Plc
Recursion Pharmaceuticals, Inc.
RegenxBio, Inc.
Takeda Pharmaceutical Company Limited
Orchard Therapeutics Plc
Magenta Therapeutics
Shire Plc
Oxyrane
NanoMedSyn
Juventas Therapeutics
GenSight Biologics
Inozyme Pharma
ONL Therapeutics
AngioChem
Cabaletta Bio
Product Type Insights
Global markets are presented by Metachromatic Leukodystrophy Treatment type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Metachromatic Leukodystrophy Treatment are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Metachromatic Leukodystrophy Treatment segment by Type

Tablet
Capsule
Others
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Metachromatic Leukodystrophy Treatment market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Metachromatic Leukodystrophy Treatment market.

Metachromatic Leukodystrophy Treatment Segment by Application

Hospital
Clinic
Laboratory
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Metachromatic Leukodystrophy Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metachromatic Leukodystrophy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Metachromatic Leukodystrophy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Metachromatic Leukodystrophy Treatment industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metachromatic Leukodystrophy Treatment.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metachromatic Leukodystrophy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Tablet
1.2.3 Capsule
1.2.4 Others
1.3 Market by Application
1.3.1 Global Metachromatic Leukodystrophy Treatment Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Laboratory
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Metachromatic Leukodystrophy Treatment Market Perspective (2017-2028)
2.2 Metachromatic Leukodystrophy Treatment Growth Trends by Region
2.2.1 Metachromatic Leukodystrophy Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Metachromatic Leukodystrophy Treatment Historic Market Size by Region (2017-2022)
2.2.3 Metachromatic Leukodystrophy Treatment Forecasted Market Size by Region (2023-2028)
2.3 Metachromatic Leukodystrophy Treatment Market Dynamics
2.3.1 Metachromatic Leukodystrophy Treatment Industry Trends
2.3.2 Metachromatic Leukodystrophy Treatment Market Drivers
2.3.3 Metachromatic Leukodystrophy Treatment Market Challenges
2.3.4 Metachromatic Leukodystrophy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metachromatic Leukodystrophy Treatment Players by Revenue
3.1.1 Global Top Metachromatic Leukodystrophy Treatment Players by Revenue (2017-2022)
3.1.2 Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Metachromatic Leukodystrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metachromatic Leukodystrophy Treatment Revenue
3.4 Global Metachromatic Leukodystrophy Treatment Market Concentration Ratio
3.4.1 Global Metachromatic Leukodystrophy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metachromatic Leukodystrophy Treatment Revenue in 2021
3.5 Metachromatic Leukodystrophy Treatment Key Players Head office and Area Served
3.6 Key Players Metachromatic Leukodystrophy Treatment Product Solution and Service
3.7 Date of Enter into Metachromatic Leukodystrophy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metachromatic Leukodystrophy Treatment Breakdown Data by Type
4.1 Global Metachromatic Leukodystrophy Treatment Historic Market Size by Type (2017-2022)
4.2 Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Type (2023-2028)
5 Metachromatic Leukodystrophy Treatment Breakdown Data by Application
5.1 Global Metachromatic Leukodystrophy Treatment Historic Market Size by Application (2017-2022)
5.2 Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Metachromatic Leukodystrophy Treatment Market Size (2017-2028)
6.2 North America Metachromatic Leukodystrophy Treatment Market Size by Country (2017-2022)
6.3 North America Metachromatic Leukodystrophy Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Metachromatic Leukodystrophy Treatment Market Size (2017-2028)
7.2 Europe Metachromatic Leukodystrophy Treatment Market Size by Country (2017-2022)
7.3 Europe Metachromatic Leukodystrophy Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metachromatic Leukodystrophy Treatment Market Size (2017-2028)
8.2 Asia-Pacific Metachromatic Leukodystrophy Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific Metachromatic Leukodystrophy Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Metachromatic Leukodystrophy Treatment Market Size (2017-2028)
9.2 Latin America Metachromatic Leukodystrophy Treatment Market Size by Country (2017-2022)
9.3 Latin America Metachromatic Leukodystrophy Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size (2017-2028)
10.2 Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 ArmaGen, Inc.
11.1.1 ArmaGen, Inc. Company Detail
11.1.2 ArmaGen, Inc. Business Overview
11.1.3 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Introduction
11.1.4 ArmaGen, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.1.5 ArmaGen, Inc. Recent Development
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Detail
11.2.2 GlaxoSmithKline Plc Business Overview
11.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Introduction
11.2.4 GlaxoSmithKline Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.2.5 GlaxoSmithKline Plc Recent Development
11.3 Recursion Pharmaceuticals, Inc.
11.3.1 Recursion Pharmaceuticals, Inc. Company Detail
11.3.2 Recursion Pharmaceuticals, Inc. Business Overview
11.3.3 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Introduction
11.3.4 Recursion Pharmaceuticals, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.3.5 Recursion Pharmaceuticals, Inc. Recent Development
11.4 RegenxBio, Inc.
11.4.1 RegenxBio, Inc. Company Detail
11.4.2 RegenxBio, Inc. Business Overview
11.4.3 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Introduction
11.4.4 RegenxBio, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.4.5 RegenxBio, Inc. Recent Development
11.5 Takeda Pharmaceutical Company Limited
11.5.1 Takeda Pharmaceutical Company Limited Company Detail
11.5.2 Takeda Pharmaceutical Company Limited Business Overview
11.5.3 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Introduction
11.5.4 Takeda Pharmaceutical Company Limited Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.5.5 Takeda Pharmaceutical Company Limited Recent Development
11.6 Orchard Therapeutics Plc
11.6.1 Orchard Therapeutics Plc Company Detail
11.6.2 Orchard Therapeutics Plc Business Overview
11.6.3 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Introduction
11.6.4 Orchard Therapeutics Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.6.5 Orchard Therapeutics Plc Recent Development
11.7 Magenta Therapeutics
11.7.1 Magenta Therapeutics Company Detail
11.7.2 Magenta Therapeutics Business Overview
11.7.3 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Introduction
11.7.4 Magenta Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.7.5 Magenta Therapeutics Recent Development
11.8 Shire Plc
11.8.1 Shire Plc Company Detail
11.8.2 Shire Plc Business Overview
11.8.3 Shire Plc Metachromatic Leukodystrophy Treatment Introduction
11.8.4 Shire Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.8.5 Shire Plc Recent Development
11.9 Oxyrane
11.9.1 Oxyrane Company Detail
11.9.2 Oxyrane Business Overview
11.9.3 Oxyrane Metachromatic Leukodystrophy Treatment Introduction
11.9.4 Oxyrane Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.9.5 Oxyrane Recent Development
11.10 NanoMedSyn
11.10.1 NanoMedSyn Company Detail
11.10.2 NanoMedSyn Business Overview
11.10.3 NanoMedSyn Metachromatic Leukodystrophy Treatment Introduction
11.10.4 NanoMedSyn Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.10.5 NanoMedSyn Recent Development
11.11 Juventas Therapeutics
11.11.1 Juventas Therapeutics Company Detail
11.11.2 Juventas Therapeutics Business Overview
11.11.3 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Introduction
11.11.4 Juventas Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.11.5 Juventas Therapeutics Recent Development
11.12 GenSight Biologics
11.12.1 GenSight Biologics Company Detail
11.12.2 GenSight Biologics Business Overview
11.12.3 GenSight Biologics Metachromatic Leukodystrophy Treatment Introduction
11.12.4 GenSight Biologics Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.12.5 GenSight Biologics Recent Development
11.13 Inozyme Pharma
11.13.1 Inozyme Pharma Company Detail
11.13.2 Inozyme Pharma Business Overview
11.13.3 Inozyme Pharma Metachromatic Leukodystrophy Treatment Introduction
11.13.4 Inozyme Pharma Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.13.5 Inozyme Pharma Recent Development
11.14 ONL Therapeutics
11.14.1 ONL Therapeutics Company Detail
11.14.2 ONL Therapeutics Business Overview
11.14.3 ONL Therapeutics Metachromatic Leukodystrophy Treatment Introduction
11.14.4 ONL Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.14.5 ONL Therapeutics Recent Development
11.15 AngioChem
11.15.1 AngioChem Company Detail
11.15.2 AngioChem Business Overview
11.15.3 AngioChem Metachromatic Leukodystrophy Treatment Introduction
11.15.4 AngioChem Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.15.5 AngioChem Recent Development
11.16 Cabaletta Bio
11.16.1 Cabaletta Bio Company Detail
11.16.2 Cabaletta Bio Business Overview
11.16.3 Cabaletta Bio Metachromatic Leukodystrophy Treatment Introduction
11.16.4 Cabaletta Bio Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022)
11.16.5 Cabaletta Bio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Tablet
    Table 3. Key Players of Capsule
    Table 4. Key Players of Others
    Table 5. Global Metachromatic Leukodystrophy Treatment Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Metachromatic Leukodystrophy Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Metachromatic Leukodystrophy Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Metachromatic Leukodystrophy Treatment Market Share by Region (2017-2022)
    Table 9. Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Metachromatic Leukodystrophy Treatment Market Share by Region (2023-2028)
    Table 11. Metachromatic Leukodystrophy Treatment Market Trends
    Table 12. Metachromatic Leukodystrophy Treatment Market Drivers
    Table 13. Metachromatic Leukodystrophy Treatment Market Challenges
    Table 14. Metachromatic Leukodystrophy Treatment Market Restraints
    Table 15. Global Metachromatic Leukodystrophy Treatment Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Metachromatic Leukodystrophy Treatment Market Share by Players (2017-2022)
    Table 17. Global Top Metachromatic Leukodystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metachromatic Leukodystrophy Treatment as of 2021)
    Table 18. Ranking of Global Top Metachromatic Leukodystrophy Treatment Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Metachromatic Leukodystrophy Treatment Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Metachromatic Leukodystrophy Treatment Product Solution and Service
    Table 22. Date of Enter into Metachromatic Leukodystrophy Treatment Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Metachromatic Leukodystrophy Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Type (2017-2022)
    Table 26. Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Type (2023-2028)
    Table 28. Global Metachromatic Leukodystrophy Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Application (2017-2022)
    Table 30. Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Application (2023-2028)
    Table 32. North America Metachromatic Leukodystrophy Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 33. North America Metachromatic Leukodystrophy Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 34. Europe Metachromatic Leukodystrophy Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 35. Europe Metachromatic Leukodystrophy Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 36. Asia-Pacific Metachromatic Leukodystrophy Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 37. Asia-Pacific Metachromatic Leukodystrophy Treatment Market Size by Region (2023-2028) & (US$ Million)
    Table 38. Latin America Metachromatic Leukodystrophy Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 39. Latin America Metachromatic Leukodystrophy Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 41. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 42. ArmaGen, Inc. Company Detail
    Table 43. ArmaGen, Inc. Business Overview
    Table 44. ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Product
    Table 45. ArmaGen, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 46. ArmaGen, Inc. Recent Development
    Table 47. GlaxoSmithKline Plc Company Detail
    Table 48. GlaxoSmithKline Plc Business Overview
    Table 49. GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Product
    Table 50. GlaxoSmithKline Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 51. GlaxoSmithKline Plc Recent Development
    Table 52. Recursion Pharmaceuticals, Inc. Company Detail
    Table 53. Recursion Pharmaceuticals, Inc. Business Overview
    Table 54. Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Product
    Table 55. Recursion Pharmaceuticals, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 56. Recursion Pharmaceuticals, Inc. Recent Development
    Table 57. RegenxBio, Inc. Company Detail
    Table 58. RegenxBio, Inc. Business Overview
    Table 59. RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Product
    Table 60. RegenxBio, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 61. RegenxBio, Inc. Recent Development
    Table 62. Takeda Pharmaceutical Company Limited Company Detail
    Table 63. Takeda Pharmaceutical Company Limited Business Overview
    Table 64. Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Product
    Table 65. Takeda Pharmaceutical Company Limited Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 66. Takeda Pharmaceutical Company Limited Recent Development
    Table 67. Orchard Therapeutics Plc Company Detail
    Table 68. Orchard Therapeutics Plc Business Overview
    Table 69. Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Product
    Table 70. Orchard Therapeutics Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 71. Orchard Therapeutics Plc Recent Development
    Table 72. Magenta Therapeutics Company Detail
    Table 73. Magenta Therapeutics Business Overview
    Table 74. Magenta Therapeutics Metachromatic Leukodystrophy Treatment Product
    Table 75. Magenta Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 76. Magenta Therapeutics Recent Development
    Table 77. Shire Plc Company Detail
    Table 78. Shire Plc Business Overview
    Table 79. Shire Plc Metachromatic Leukodystrophy Treatment Product
    Table 80. Shire Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 81. Shire Plc Recent Development
    Table 82. Oxyrane Company Detail
    Table 83. Oxyrane Business Overview
    Table 84. Oxyrane Metachromatic Leukodystrophy Treatment Product
    Table 85. Oxyrane Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 86. Oxyrane Recent Development
    Table 87. NanoMedSyn Company Detail
    Table 88. NanoMedSyn Business Overview
    Table 89. NanoMedSyn Metachromatic Leukodystrophy Treatment Product
    Table 90. NanoMedSyn Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 91. NanoMedSyn Recent Development
    Table 92. Juventas Therapeutics Company Detail
    Table 93. Juventas Therapeutics Business Overview
    Table 94. Juventas Therapeutics Metachromatic Leukodystrophy TreatmentProduct
    Table 95. Juventas Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 96. Juventas Therapeutics Recent Development
    Table 97. GenSight Biologics Company Detail
    Table 98. GenSight Biologics Business Overview
    Table 99. GenSight Biologics Metachromatic Leukodystrophy TreatmentProduct
    Table 100. GenSight Biologics Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 101. GenSight Biologics Recent Development
    Table 102. Inozyme Pharma Company Detail
    Table 103. Inozyme Pharma Business Overview
    Table 104. Inozyme Pharma Metachromatic Leukodystrophy TreatmentProduct
    Table 105. Inozyme Pharma Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 106. Inozyme Pharma Recent Development
    Table 107. ONL Therapeutics Company Detail
    Table 108. ONL Therapeutics Business Overview
    Table 109. ONL Therapeutics Metachromatic Leukodystrophy TreatmentProduct
    Table 110. ONL Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 111. ONL Therapeutics Recent Development
    Table 112. AngioChem Company Detail
    Table 113. AngioChem Business Overview
    Table 114. AngioChem Metachromatic Leukodystrophy TreatmentProduct
    Table 115. AngioChem Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 116. AngioChem Recent Development
    Table 117. Cabaletta Bio Company Detail
    Table 118. Cabaletta Bio Business Overview
    Table 119. Cabaletta Bio Metachromatic Leukodystrophy TreatmentProduct
    Table 120. Cabaletta Bio Revenue in Metachromatic Leukodystrophy Treatment Business (2017-2022) & (US$ Million)
    Table 121. Cabaletta Bio Recent Development
    Table 122. Research Programs/Design for This Report
    Table 123. Key Data Information from Secondary Sources
    Table 124. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Metachromatic Leukodystrophy Treatment Market Share by Type: 2021 VS 2028
    Figure 2. Tablet Features
    Figure 3. Capsule Features
    Figure 4. Others Features
    Figure 5. Global Metachromatic Leukodystrophy Treatment Market Share by Application in 2021 & 2028
    Figure 6. Hospital Case Studies
    Figure 7. Clinic Case Studies
    Figure 8. Laboratory Case Studies
    Figure 9. Others Case Studies
    Figure 10. Metachromatic Leukodystrophy Treatment Report Years Considered
    Figure 11. Global Metachromatic Leukodystrophy Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 12. Global Metachromatic Leukodystrophy Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Metachromatic Leukodystrophy Treatment Market Share by Region: 2021 VS 2028
    Figure 14. Global Metachromatic Leukodystrophy Treatment Market Share by Players in 2021
    Figure 15. Global Top Metachromatic Leukodystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metachromatic Leukodystrophy Treatment as of 2021)
    Figure 16. The Top 10 and 5 Players Market Share by Metachromatic Leukodystrophy Treatment Revenue in 2021
    Figure 17. North America Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 18. North America Metachromatic Leukodystrophy Treatment Market Share by Country (2017-2028)
    Figure 19. United States Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Canada Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Metachromatic Leukodystrophy Treatment Market Share by Country (2017-2028)
    Figure 23. Germany Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. France Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. U.K. Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Italy Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Russia Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Nordic Countries Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Asia-Pacific Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Asia-Pacific Metachromatic Leukodystrophy Treatment Market Share by Region (2017-2028)
    Figure 31. China Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Japan Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. South Korea Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Southeast Asia Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. India Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Australia Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Latin America Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Latin America Metachromatic Leukodystrophy Treatment Market Share by Country (2017-2028)
    Figure 39. Mexico Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Brazil Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Share by Country (2017-2028)
    Figure 43. Turkey Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Saudi Arabia Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. ArmaGen, Inc. Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 46. GlaxoSmithKline Plc Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 47. Recursion Pharmaceuticals, Inc. Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 48. RegenxBio, Inc. Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 49. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 50. Orchard Therapeutics Plc Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 51. Magenta Therapeutics Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 52. Shire Plc Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 53. Oxyrane Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 54. NanoMedSyn Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 55. Juventas Therapeutics Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 56. GenSight Biologics Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 57. Inozyme Pharma Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 58. ONL Therapeutics Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 59. AngioChem Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 60. Cabaletta Bio Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2017-2022)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$2900
This license allows only one user to access the PDF.

Electronic (PDF)
$4350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$5800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Samsung SD
SIMILAR REPORTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Add to Cart

Global Parkinson Disease Drug Market Size Status and Forecast 2021 2027
Global Parkinson Disease Drug Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-39X2260
Thu Sep 22 00:00:00 UTC 2022

Add to Cart

Add to Cart